HUP0300547A2 - Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállítására - Google Patents

Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállítására

Info

Publication number
HUP0300547A2
HUP0300547A2 HU0300547A HUP0300547A HUP0300547A2 HU P0300547 A2 HUP0300547 A2 HU P0300547A2 HU 0300547 A HU0300547 A HU 0300547A HU P0300547 A HUP0300547 A HU P0300547A HU P0300547 A2 HUP0300547 A2 HU P0300547A2
Authority
HU
Hungary
Prior art keywords
alkyl
carbon atoms
amino
methyl
carbon
Prior art date
Application number
HU0300547A
Other languages
English (en)
Inventor
Carolyn M. Discafani-Marro
Philip Frost
Original Assignee
American Cyanamid Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co. filed Critical American Cyanamid Co.
Publication of HUP0300547A2 publication Critical patent/HUP0300547A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

A találmány (1) általános képletű ciano-kinolinok és gyógyászatilagelfogadható sóinak alkalmazására vonatkozik gyógyszer előállítására,amellyel vastagbél polip kezelhető vagy gátolható. Az (1) általánosképletben a szubsztituensek jelentése az alábbiakban megadott. Xjelentése adott esetben egy vagy több 1-6 szénatomos alkilcsoporttalszubsztituált 3-7 szénatomos cikloalkilcsoport, vagy piridinil-,pirimidinil- vagy fenilcsoport, ahol a piridinit-, pirimidinil- vagyfenilgyűrű adott esetben mono-, di- vagy tri-szubsztituált lehet, nértéke 0-1; Y jelentése -NH-, -0-, -S- vagy -NR-; R jelentése 1-6szénatomos alkilcsoport; R1 R2, R3 és R4 jelentése egymástólfüggetlenül halogén- vagy hidrogénatom, 1-6 szénatomos alkil-, 2-6szénatomos alkenil-, 2-6 szénatomos alkinil-, 2-6 szénatomosalkeniloxi-, 2-6 szénatomos alkinil-oxi-, hidroxi-metil-,halogénmetil-, 1-6 szénatomos alkanoil-oxi-, 3-8 szénatomos alkenoil-oxi-, 3-8 szénatomos alkinoil-oxi-, 2-7 szénatomos alkanoil-oxi-metil-, 4-9 szénatomos alkenoil-oxi-metil-, 4-9 szénatomos alkinoil-oxi-metil-, 2-7 szénatomos alkoxi-metil 1-6 szénatomos alkoxi-, 1-6szénatomos alkil-tio-, 1-6 szénatomos alkil-szulfinil-, 1-6 szénatomosalkil-szulfonil-, 1-6 szénatomos alkil-szulfonamido-, 2-6 szénatomosalkenil-szulfonamido-, 2-6 szénatomos alkinil-szulfonamido-hidroxil-,trifluor-metil-, ciano-, nitro-, karboxil-, 2-7 szénatomoskarboalkoxi-, 2-7 szénatomos karboalkil-, fenoxi-, fenil-, tio-fenoxi-, benzil-, amino-, hidroxi-amino-, 1-4 szénatomos alkoxi-amino-, 1-6 szénatomos alkil-amino-, 2-12 szénatomos dialkil-amino-,1-4 szénatomos aminoalkil-, 2-7 szénatomos N-alkil-amino-alkil-, 3-14szénatomos N,N-dialkil-amino-alkil-, fenil-amino-, benzilaminocsoportlehet. Ó
HU0300547A 2000-03-13 2001-03-06 Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállítására HUP0300547A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52419600A 2000-03-13 2000-03-13
PCT/US2001/007068 WO2001068186A2 (en) 2000-03-13 2001-03-06 Use of cyanoquinolines for treating or inhibiting colonic polyps

Publications (1)

Publication Number Publication Date
HUP0300547A2 true HUP0300547A2 (hu) 2003-07-28

Family

ID=24088181

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300547A HUP0300547A2 (hu) 2000-03-13 2001-03-06 Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállítására

Country Status (23)

Country Link
EP (1) EP1263503B1 (hu)
JP (1) JP2003526686A (hu)
KR (2) KR20080009294A (hu)
CN (1) CN1190197C (hu)
AR (1) AR035482A1 (hu)
AT (1) ATE308364T1 (hu)
AU (2) AU4545201A (hu)
BR (1) BR0109165A (hu)
CA (1) CA2402742C (hu)
DE (1) DE60114580T2 (hu)
DK (1) DK1263503T3 (hu)
EA (1) EA200200976A1 (hu)
ES (1) ES2248302T3 (hu)
HK (1) HK1048775B (hu)
HU (1) HUP0300547A2 (hu)
IL (2) IL151249A0 (hu)
MX (1) MXPA02008836A (hu)
NO (1) NO20024356L (hu)
NZ (1) NZ521117A (hu)
PL (1) PL202873B1 (hu)
TW (1) TWI262805B (hu)
WO (1) WO2001068186A2 (hu)
ZA (1) ZA200208178B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
EP1477481B1 (en) * 2002-01-28 2009-07-22 Ube Industries, Ltd. Process for producing quinazolin-4-one derivative
JP4361375B2 (ja) 2002-02-05 2009-11-11 ワイス Ｎ−アシル−２−アミノ−４−アルコキシ−５−ニトロ安息香酸の合成方法
CN1304374C (zh) * 2002-04-30 2007-03-14 永进药品工业株式会社 可用做caspase－3抑制剂的喹啉衍生物及其制备方法和药用组合物
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
EP1625121B1 (en) 2002-12-20 2010-02-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
JP4638436B2 (ja) 2003-09-26 2011-02-23 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターおよびその使用
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR20080016604A (ko) * 2005-05-25 2008-02-21 와이어쓰 6-알킬아미노퀴놀린 유도체의 합성 방법
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
DE102006029446A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-substituierte-Chinoline als Kinase-Inhibitoren
DE102006029445A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-Cyano-chinoline als Kinase-Inhibitoren
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
EA201270051A1 (ru) * 2009-06-25 2012-05-30 Амген Инк. Гетероциклические соединения и их применения
EP2451445B1 (en) 2009-07-06 2019-04-03 Boehringer Ingelheim International GmbH Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Ｚｎｆ１４３阻害活性を有する化合物およびその利用
BR112017021869A2 (pt) * 2015-04-10 2018-12-11 Araxes Pharma Llc compostos quinazolina substituídos e métodos de uso dos mesmos
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
CN108779097A (zh) 2015-11-16 2018-11-09 亚瑞克西斯制药公司 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3630746A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
PT1202746E (pt) * 1999-08-12 2007-01-31 Wyeth Corp Composição contendo um nsaid e um inibidor de cinase de efgr para o tratamento de inibição pólipos do cólon e do cancro colo-rectal

Also Published As

Publication number Publication date
KR100817423B1 (ko) 2008-03-27
ES2248302T3 (es) 2006-03-16
KR20020092987A (ko) 2002-12-12
NO20024356L (no) 2002-11-12
PL202873B1 (pl) 2009-07-31
CN1190197C (zh) 2005-02-23
AR035482A1 (es) 2004-06-02
CA2402742C (en) 2009-05-12
ZA200208178B (en) 2004-02-11
AU2001245452B2 (en) 2005-05-05
DE60114580D1 (de) 2005-12-08
DK1263503T3 (da) 2006-02-13
TWI262805B (en) 2006-10-01
KR20080009294A (ko) 2008-01-28
IL151249A (en) 2008-06-05
HK1048775A1 (en) 2003-04-17
CN1429126A (zh) 2003-07-09
NO20024356D0 (no) 2002-09-12
HK1048775B (zh) 2006-01-20
BR0109165A (pt) 2003-04-22
EA200200976A1 (ru) 2003-02-27
DE60114580T2 (de) 2006-07-27
EP1263503B1 (en) 2005-11-02
NZ521117A (en) 2005-02-25
AU4545201A (en) 2001-09-24
IL151249A0 (en) 2003-04-10
EP1263503A2 (en) 2002-12-11
MXPA02008836A (es) 2003-02-10
WO2001068186A3 (en) 2002-01-17
ATE308364T1 (de) 2005-11-15
WO2001068186A2 (en) 2001-09-20
CA2402742A1 (en) 2001-09-20
JP2003526686A (ja) 2003-09-09
PL363072A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
HUP0300547A2 (hu) Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállítására
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
HUP0101372A2 (hu) Triszubsztituált 1,3,5-triazin-származékok HIV-fertőzések kezelésére
AP2001002079A0 (en) Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents.
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
JO2282B1 (en) Oxazole derivatives
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
ATE361287T1 (de) Neue indol-2-on derivate
GT199900139A (es) Derivados de quinolin-2-ona ùtiles como agentes contra el càncer.
HUP0302480A2 (hu) Piridinonszármazékok ateroszklerózis kezelésére, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
HUP0400208A2 (hu) N-formil hidroxil-amin vegyületek, eljárás az előállításukra és ezeket tartalmazó készítmények
CY1110343T1 (el) 2-(πυριδιν-2-υλο)-πυριμιδινες και η χρησιμοποιηση του για την καταπολεμηση επιζημιων μυκητων
HUP0402657A2 (hu) Alzheimer-kór kezelésére vagy megelőzésére vagy az amiloid fehérje rostképzésének gátlására adható nitrogéntartalmú heteroaril vegyületek és az ezeket tartalmazó gyógyászati készítmények
HUP0500201A2 (hu) Policiklusos vegyületek, mint potenciális alfa2-adrenoceptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
WO2003070728A3 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
BRPI0407441A (pt) 4-[(2,4-dicloro-5-metóxifenil)amino]-6-alcóxi-3-quinoli nacarbonitrilos para o tratamento de lesão isquêmica
RS44004A (en) Processes for the preparation of substituted bicyclid derivatives for the treatment of abnormal cell growth
ATE509905T1 (de) Benzamidderivate
HUP0300265A2 (hu) Aril- és heteroaril-szulfonátok, eljárás előállításukra és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees